S33005
Chemical compound
Clinical data | |
---|---|
Other names | (–)-1-(1-dimethylaminomethyl) 5-methoxybenzocyclobutan-1-yl) cyclohexanol |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
Chemical and physical data | |
Formula | C18H27NO2 |
Molar mass | 289.419 g·mol−1 |
3D model (JSmol) |
|
| |
|
S33005 is a serotonin–norepinephrine reuptake inhibitor (SNRI) that was under development by Servier for the treatment of depression and related disorders. It is structurally related to venlafaxine but has a more complex molecular structure. Venlafaxine appears to be a sigma modulator,[1] but it is not known if S33005 shares this activity.
Synthesis
"The 1-cyano-benzocyclobutenes used as starting material are obtained, for example, by subjecting a β-[orthohalogeno-phenyl]-propionitrile to intramolecular condensation in the presence of potassium amide, or by brominating a benzocyclobutene in position 1 with N-bromosuccinimide, followed by exchange of the bromine atom for a cyano group by means of sodium cyanide."[2]
See also
References
External links
- PubMed search
- Binding Database
- The patent and synthesis discussion can be found in U.S. patent 6,107,345
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
|
Retrieved from "https://en.wikipedia.org/w/index.php?title=S33005&oldid=1188194083"